Summit Therapeutics to Host R&D Day 11 October 2017
October 02 2017 - 7:00AM
Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery
and development company advancing therapies for Duchenne muscular
dystrophy and Clostridium difficile infection (‘CDI’), will host an
R&D Day featuring presentations from experts in quantitative
muscle image analysis and CDI alongside Summit’s management on 11
October 2017 in New York City.
This event is open to analysts, institutional
investors and members of the press. For more information, email
investors@summitplc.com.
A live audio webcast of the presentation will be
available through the Investors section on the Company’s website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed
on Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
|
Tel: +44 (0)1235 443
951 +1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser)Liam Murray / Tony
Rawlinson |
|
Tel: +44 (0)20 7213
0880 |
|
|
|
N+1
Singer (Broker)Aubrey Powell / Lauren Kettle
|
|
Tel: +44 (0)20 7496
3000 |
|
|
|
MacDougall
Biomedical Communications(US media contact)Karen
Sharma |
|
Tel: +1 781 235 3060
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey
Neville |
|
Tel: +44 (0)20 3709
5700summit@consilium-comms.com |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2023 to Apr 2024